Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 18/20 | 0.58 |
| ▸ | HCRTR2 | O43614 | 13/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL262353 | 0.91 | HCRTR1 (0.69) | HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL3385234 | 0.91 | HCRTR1 (0.69) | HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL3385613 | 0.89 | CYP3A4 (0.63) | HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL3387575 | 0.89 | HCRTR1 (0.68) | HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL3388555 | 0.88 | CYP3A4 (0.73) | HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL7912839 | 0.88 | CYP3A4 (0.73) | HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL2471240 | 0.88 | HCRTR1 (0.62) | HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL7917283 | 0.88 | HCRTR1 (0.62) | HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL2469245 | 0.87 | HCRTR1 (0.57) | HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL3386463 | 0.87 | CYP3A4 (0.59) | HCRTR1HCRTR2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144760-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-06-10 | — | — | US | disclosed |
| US-20100144760-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-06-10 | — | — | US | disclosed |
| US-20100144760-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-06-10 | — | — | US | disclosed |
| WO-2010063663-A1 | N-{[(IR,4S,6R-3-(2-PYRIDINYLCARBONYL)-3-AZABICYCLO [4.1.0]HEPT-4-YL] METHYL}-2-HETEROARYLAMINE DERIVATIVES AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144760-A1 | NOVEL COMPOUNDS | HTR3B, HTR1B, HTR2B | HCRTR1 2016/4885HCRTR2 1425/4885CYP3A4 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.